Cell Disruption Enzymatic Lysis Patents: Leaders & White Space 2026
Cell disruption and enzymatic lysis patents: who leads and where claim space is still open
No single company dominates. the ranked leader holds 50 records and the top 5 combined account for just 11.8% of all 1,764 records in scope. Filings rose to a peak of 91 in 2019, then declined; the 2021-to-2024 span shows 53 down to 17 records, a -68% move that the hero card reflects exactly. 2025 and 2026 figures are still filling in under the publication lag and should not be read as confirming a continued decline.
- 1BECTON DICKINSON & CO2.8%
- 2CENTELION SAS2.4%
- 3SAFEGUARD BIOSYSTEMS HOLDINGS LTD2.4%
- 4GEN PROBE INC2.3%
- 5DSM IP ASSETS BV1.8%
See the full cell disruption enzymatic lysis analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in cell disruption and enzymatic lysis?
The assignee ranking covers 100 companies by record count, with the leader holding 50 records against a field of 1,764 total records in scope. The top 5 combined account for 11.8% of all records, which means no single company controls a dominant share of the claim space. This is a fragmented field with a long tail of mid-sized and single-filing entrants rather than a market gated by two or three large portfolios.
Is patent filing activity in cell disruption and enzymatic lysis growing or shrinking?
Filing volume peaked at 91 records in 2019 and has declined since, with the 2021-to-2024 span showing a drop from 53 to 17 records, a -68% move. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by roughly 18 months, so the most recent years should not be read as proof the decline is continuing at the same pace. Treat the 2024 figure as the most recent reliable data point.
What technology areas overlap most with cell disruption patents?
Beyond the core C12N microorganism-handling class, which appears in 97.2% of the 1,764 records, the largest overlaps are with C12Q enzyme and DNA measurement (28.5%), C12P fermentation and enzymatic synthesis (26.2%), and C12M bioreactor and enzyme apparatus (21.3%). This spread shows that lysis method claims are frequently bundled with downstream measurement or synthesis steps rather than filed as standalone mechanical claims. A record can carry more than one class, so these percentages do not sum to 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Cell Disruption Enzymatic Lysis covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.